The Mexican Association of Pharmaceutical Laboratories (AMELAF) received authorization to use the “Made in Mexico” label granted by the Ministry of Economy to promote national industry and local consumption.
“The Made in Mexico label represents the strength, talent, and capacity of our national pharmaceutical industry. At AMELAF, we proudly embrace this distinction, which acknowledges the quality of what we produce in the country and reaffirms our commitment to competitive, world-class Mexican manufacturing,” said Juan de Villafranca, the association’s executive president.
What is AMELAF?
Founded in 2003, AMELAF represents 49 companies that are 100% Mexican, owners of more than 80 manufacturing plants across the country, mainly dedicated to producing generic medicines.
Te podría interesar
The association also works in coordination with the pharmaceutical industry, the health authority Cofepris, and the health sector to improve public access to safe and effective treatments.
With the “Made in Mexico” label, AMELAF strengthens its role as a promoter and coordinator of the Mexican pharmaceutical industry, supporting the work of its member laboratories.
Context: According to Trade Gov, a U.S. commercial guide, there are approximately 400 laboratories that manufacture pharmaceuticals in Mexico.
Despite outstanding debts, they continue supplying medicines
AMELAF has been a key player in the country’s pharmaceutical industry, positioning itself on issues related to public procurement, medicine supply, government debt, and the strengthening of national manufacturing.
The association has reported that, despite the government’s multimillion-peso debts, laboratories continue delivering medicines to avoid supply disruptions for patients.
“With AMELAF laboratories, the government’s outstanding debt amounts to about 5 billion pesos; this year’s debts are moving forward, but the problem is that these could jeopardize the operation of national laboratories. Without income, they have debts or begin accumulating debts with suppliers; it’s not the same to owe a multinational as it is to owe a national company,” Villafranca said in an interview with La Silla Rota.
The association also warned that national laboratories are at a disadvantage compared to subsidies received by foreign companies.
Additionally, it led a pharmaceutical summit in Washington, D.C. as part of a strategy to increase the presence of Mexican laboratories in the U.S. market.
Why is this important?
AMELAF’s use of the “Made in Mexico” label strengthens confidence in national pharmaceutical manufacturing, supporting the quality of medicines produced in the country, boosting the visibility of domestic laboratories, and reinforcing their ability to compete in both local and international markets.
djh